Sintilimab for relapsed/refractory extranodal NK/T cell lymphoma: a multicenter, single-arm, phase 2 trial (ORIENT-4)

[1]  M. Lunning,et al.  Checkpoint inhibition in ENKTL: Kno_le_ge G_ps. , 2020, Blood.

[2]  C. Ong,et al.  Avelumab for the treatment of relapsed or refractory extranodal NK/T-cell lymphoma: an open-label phase 2 study. , 2020, Blood.

[3]  Bo Peng,et al.  Durable blockade of PD-1 signaling links preclinical efficacy of sintilimab to its clinical benefit , 2019, mAbs.

[4]  Lei Zhan,et al.  How to differentiate pseudoprogression from true progression in cancer patients treated with immunotherapy. , 2019, American journal of cancer research.

[5]  M. Takahara,et al.  Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type: Basic Science and Clinical Progress , 2019, Front. Pediatr..

[6]  S. Raza,et al.  Pembrolizumab in newly diagnosed EBV-negative extranodal natural killer/T-cell lymphoma: A case report. , 2019, Molecular and clinical oncology.

[7]  S. Ansell.  Sintilimab: another effective immune checkpoint inhibitor in classical Hodgkin lymphoma. , 2019, The Lancet. Haematology.

[8]  M. Weller,et al.  Pseudoprogression: fact or wishful thinking in neuro-oncology? , 2018, The Lancet. Oncology.

[9]  O. Mioduszewska,et al.  T-cell lymphomas. , 2018, Archiv fur Geschwulstforschung.

[10]  Jianming Xu,et al.  A first-in-human phase 1a trial of sintilimab (IBI308), a monoclonal antibody targeting programmed death-1 (PD-1), in Chinese patients with advanced solid tumors. , 2018 .

[11]  K. Young,et al.  Activity of pembrolizumab in relapsed/refractory NK/T-cell lymphoma , 2018, Journal of Hematology & Oncology.

[12]  Y. Ko,et al.  Beyond first-line non-anthracycline-based chemotherapy for extranodal NK/T-cell lymphoma: clinical outcome and current perspectives on salvage therapy for patients after first relapse and progression of disease , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[13]  Xiao-liu Jiang,et al.  Successful treatment with anti-programmed-death-1 antibody in a relapsed natural killer/T-cell lymphoma patient with multi-line resistance: a case report , 2017, BMC Cancer.

[14]  R. V. Van Heertum,et al.  Lugano 2014 criteria for assessing FDG-PET/CT in lymphoma: an operational approach for clinical trials , 2017, Drug design, development and therapy.

[15]  P. Khong,et al.  PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK/T-cell lymphoma failing l-asparaginase. , 2017, Blood.

[16]  K. Tobinai,et al.  Clinical Features and Current Optimal Management of Natural Killer/T-Cell Lymphoma. , 2017, Hematology/oncology clinics of North America.

[17]  W. Xu,et al.  Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China , 2017, Journal of Hematology & Oncology.

[18]  P. Khong,et al.  Low‐dose pembrolizumab induced remission in patients with refractory classical Hodgkin lymphoma , 2017, British journal of haematology.

[19]  R. Advani,et al.  Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy. , 2016, Blood.

[20]  Zenggang Pan,et al.  Extranodal NK/T Cell Lymphoma, Nasal Type (ENKTL-NT): An Update on Epidemiology, Clinical Presentation, and Natural History in North American and European Cases , 2016, Current Hematologic Malignancy Reports.

[21]  J. Wolchok,et al.  Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  Sin-Ho Jung,et al.  A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a multicentre, retrospective analysis. , 2016, The Lancet. Oncology.

[23]  Xue Chen,et al.  PD-1 Blockade Can Restore Functions of T-Cells in Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma In Vitro , 2015, PloS one.

[24]  Z. Ning,et al.  Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[25]  W. Liang,et al.  EBV-driven LMP1 and IFN-γ up-regulate PD-L1 in nasopharyngeal carcinoma: Implications for oncotargeted therapy , 2014, Oncotarget.

[26]  R. Gascoyne,et al.  Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  Y. Ko,et al.  Gemcitabine alone and/or containing chemotherapy is efficient in refractory or relapsed NK/T-cell lymphoma , 2013, Investigational New Drugs.

[28]  R. Suzuki,et al.  Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  M. Winget,et al.  Utilization of oncology services and receipt of treatment: a comparison between patients with breast, colon, rectal, or lung cancer. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[30]  P. Gaulard,et al.  Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK/T-cell lymphoma, a phase 2 study. , 2011, Blood.

[31]  T. Okamura,et al.  Phase I study of dexamethasone, methotrexate, ifosfamide, l‐asparaginase, and etoposide (SMILE) chemotherapy for advanced‐stage, relapsed or refractory extranodal natural killer (NK)/T‐cell lymphoma and leukemia , 2008, Cancer science.

[32]  Connils.  Lugano , 1877 .

[33]  Wei Li,et al.  Safety and activity of sintilimab in patients with relapsed or refractory classical Hodgkin lymphoma (ORIENT-1): a multicentre, single-arm, phase 2 trial. , 2019, The Lancet. Haematology.

[34]  J. Kim,et al.  Expression of programmed cell death 1 and programmed cell death ligand 1 in extranodal NK/T-cell lymphoma, nasal type , 2016, Annals of Hematology.